Cerebrotendinous xanthomatosis (a rare lipid storage disorder): a case report
© Razi et al. 2016
Received: 9 December 2015
Accepted: 22 March 2016
Published: 19 April 2016
Cerebrotendinous xanthomatosis is a very rare autosomal recessive lipid storage disorder affecting bile acid biosynthesis. It is manifested by subtle neurological and non-neurological symptoms due to abnormal tissue lipid deposition. Diagnosis is usually delayed but early diagnosis and replacement therapy can prevent devastating neurological sequelae.
We present a case of a 25-year-old Asian Indian woman who presented with gait difficulty, fusiform swellings of bilateral tendo-Achilles and infrapatellar tendons, along with history of bilateral cataract surgery 1 year earlier. The diagnosis was made on the basis of clinical, biochemical, imaging, and histopathological analysis and replacement therapy was started.
The peculiarity of the present case is the absence of any neurological manifestations which are usually the early clues to the diagnosis of cerebrotendinous xanthomatosis. The present case report emphasizes the fact that early age bilateral cataracts along with bilateral tendo-Achilles xanthomas can be early pointers toward the diagnosis of cerebrotendinous xanthomatosis.
KeywordsCerebrotendinous xanthomatosis CYP27A1 Xanthoma Chenodeoxycholic acid Cholestanol
Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive lipid disorder: phenotype Online Mendelian Inheritance in Man (OMIM)#213700, gene OMIM#606530 . It is caused by mutations in gene CYP27A1 located on the chromosome 2q33-qter causing lack of enzyme mitochondrial sterol 27-hydroxylase . CYP27A1 plays a pivotal role in cholesterol side chain oxidation during the synthesis of chenodeoxycholic acid (CDCA) which is a bile acid . Therefore perturbations in CYP27A1 gene result in reduced enzymatic activity causing impairment of cholesterol side chain oxidation finally culminating in excessive production and abnormal deposition of cholestanol in various tissues [1, 2]. The classical triad of the syndrome consists of premature bilateral cataract, tendon xanthomas (predominantly involving tendo-Achilles) and various neurological abnormalities . A recent study by Appadurai et al.  stated that in the absence of epidemiological studies the disease is considered to be exceedingly rare but it is actually underreported. This group studied the Exome Aggregation Consortium (ExAC) cohort of 60,000 unrelated adults globally for the frequency of 57 reported pathogenic variants of CYP27A1 along with 29 additional variants through bioinformatics; they estimated that the incidence of CTX ranged from 1:134,970 to 1:461,358 in Europe, 1:263,222 to 1:468,624 in Africa, 1:71,677 to 1:148,914 in the USA, 1:64,267 to 1:64,712 in East Asia, and 1:36,072 to 1:468,624 in South Asia . However, another recent study by Ragno et al. stated that more than 300 cases have been reported so far with approximately 50 mutations with little correlation between genotype and phenotype . The mean age of onset of the symptoms is 19 years while the mean age at diagnosis is 35 years representing a lag of 16 years in the diagnosis . A recent study of 19 patients from 15 unrelated Italian families by Mignarri et al. estimated the median age at diagnosis to be 32 years while the mean age was 32.5±10.4 years . Replacement therapy with CDCA delays or even reverses the progression of the disease ; however, because there is a lag period between the onset of symptoms and the mean age of diagnosis , early diagnosis is required to prevent devastating neurological sequelae and other complications such as premature atherosclerosis and osteoporosis. So a high index of suspicion should be kept in any patient encountered with the classical triad as illustrated in the present case report.
A 25-year-old Asian Indian woman presented with complaints of swellings behind both her ankles and in front of both her knees for the last 2 years. These swellings had an insidious onset; they were painless, gradually progressive, and caused difficulty in walking for the last 1 year. She had history of bilateral cataract surgery 1 year earlier. There was no history of childhood diarrhea, seizures, cerebellar symptoms, psychiatric manifestations, mental retardation, or premature atherosclerosis. There was no family history of similar complaints.
CTX is a rare autosomal recessive inborn error of bile acid synthesis first reported by Von Bogaert in 1937. The disease is caused by mutation in gene CYP27A1 located on chromosome 2q33-qter leading to a lack of mitochondrial sterol 27-hydroxylase enzyme at the inner mitochondrial membrane in almost all cells of the body [7, 8]. Absence of sterol 27-hydroxylase enzyme activity causes deficiency of CDCA and cholic acid leading to a loss of feedback inhibition of rate-limiting enzyme cholesterol 7α-hydroxylase (CYP7A1) of bile synthesis, which results in excess production of cholestanol which gets deposited in various tissues [1–3].
The diagnosis is delayed due to subtle manifestations and the rarity of the disease . The disease has multiorgan involvement such as bilateral premature cataracts, intractable childhood diarrhea, tendon xanthomas, neurological abnormalities, and premature atherosclerosis. The usual manifestations are due to deposition of excess cholestanol and cholesterol in the affected tissues [1, 3]. Our patient presented with bilateral tendo-Achilles tuberous xanthomas along with premature bilateral cataracts but no neurological abnormalities.
Familial hypercholesterolemia and sitosterolemia are the two important differential diagnoses of CTX. CTX is differentiated clinically from other disorders of lipid metabolism because of juvenile cataracts, progressive neurological symptoms, mild pulmonary insufficiency, and increased levels of cholestanol . In the absence of tendinous xanthomas, CTX may be confused with Marinesco–Sjögren syndrome as it also presents with early age cataracts, cerebellar ataxia, neuromuscular weakness, and mental retardation but it can be differentiated from CTX by short stature, skeletal anomalies and hypergonadotropic hypogonadism [10, 11].
The laboratory findings include a normal or reduced serum cholesterol level, increased serum cholestanol, increased 7α-hydroxy-4-cholesten-3-one (7αC4), increased lathosterol, increased plant sterols (campesterol, sitosterol), increased serum and urinary bile acid alcohols but reduced serum CDCA and 27-hydroxycholesterol (27-OHC) . Typical MRI findings are bilateral T2 and FLAIR hyperintense, nonhomogeneous signals in dentate nuclei and surrounding cerebellum. There are diffuse or focal white matter abnormalities along with cerebral and cerebellar atrophy [1, 3, 10]. MRS studies reveal increased lactate and lipid peaks in FLAIR sequence-hypointense lesions, and diffusely decreased NAA peaks. Microscopy reveals foamy cells admixed with inflammatory cells and giant cells surrounding cholesterol clefts . These laboratory findings exactly correlate with those of our patient in the present discussion.
The treatment consists of replacement therapy, surgery and other symptomatic therapies. The replacement therapy can prevent or even reverse neurological complications and involves administration of bile acids such as CDCA, ursodeoxycholic acid, cholic acid, and taurocholic acid. Among these, CDCA is considered the drug of choice. Hydroxymethylglutaryl-CoA (HMG-CoA) synthase inhibitors are considered to enhance the effect of replacement therapy. Surgery may deteriorate gait imbalance and does not prevent neurological complications .
CTX is a rare and underreported lipid storage disorder. Although it is medically manageable, a delay in diagnosis can be devastating for the patient so early diagnosis based on a high index of suspicion is imperative for better management.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
The authors thank the team of Department of Endocrinology L.L.R.M. Medical College, Meerut for providing support and helping in the preparation of the manuscript.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Nie S, Chen G, Cao X, Zhang Y. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J Rare Dis. 2014;9(1):179.View ArticlePubMedPubMed CentralGoogle Scholar
- Appadurai V, DeBarber A, Chiang PW, Patel SB, Steiner RD, Tyler C, et al. Apparent underdiagnosis of cerebrotendinous xanthomatosis revealed by analysis of ~60,000 human exomes. Mol Genet Metab. 2015;116(4):298–304.View ArticlePubMedGoogle Scholar
- Sandeep P, Jayakrishnan C, Sadanan S, Sreekumar S, Thulasidharan NK. Cerebrotendinous xanthomatosis: a treatable neurodegenerative disease. J Assoc Physicians India. 2009;57:716–7.PubMedGoogle Scholar
- Ragno M, Di Marzio F, Fuccio C, Pianese L, Cozzolino V, Carboni T, et al. Cerebellar hypometabolism with normal structural findings in cerebrotendinous xanthomatosis. A case report. Clin Neurol Neurosurg. 2015;139:221–3.View ArticlePubMedGoogle Scholar
- Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR, Pardo J, Arias M, Ares-Luque A, et al. Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol. 2011;18(10):1203–11.View ArticlePubMedGoogle Scholar
- Mignarri A, Magni A, Del Puppo M, Gallus GN, Björkhem I, Federico A, et al. Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2015;8:1–9.Google Scholar
- Lorbek G, Lewinska M, Rozman D. Cytochrome P450s in the synthesis of cholesterol and bile acids – from mouse models to human diseases. FEBS J. 2012;279(9):1516–33.View ArticlePubMedGoogle Scholar
- Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72(1):137–74.View ArticlePubMedGoogle Scholar
- Chalès G, Coiffier G, Guggenbuhl P. Rare thesaurismosis and xanthomatosis. Best Pract Res Clin Rheumatol. 2011;25(5):683–701.View ArticlePubMedGoogle Scholar
- Jha S, Khateeb M, Sonker K. Cerebrotendinous xanthomatosis, early diagnosis mandatory: Report of a case from North India. Neurol Asia. 2008;13:125–8.Google Scholar
- Slavotinek A, Goldman J, Weisiger K, Kostiner D, Golabi M, Packman S, et al. Marinesco–Sjögren syndrome in a male with mild dysmorphism. Am J Med Genet A. 2005;133(2):197–201.View ArticleGoogle Scholar